Skip to main content

Table 1 Patient and tumor characteristics

From: [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes

Pt.

Age (yr)

stage

Gleason

iPSA

PSA nadir

dt PSA

(mo.)

PSA before FEC

PET/CT

Previous therpay

1

73

cT2 cN0

7

11,5

-

3

11,5

pos. (P)

-

2

59

cT2 cN0

6

9,1

-

7

9,1

pos. (P)

-

3

64

cT3 cN0

n.a.

731

-

n.a.

36

pos. (P, Bo., Bl)

AHT

4

77

cT3a cN0

7

3,4

-

n.a.

3,4

pos. (P)

AHT

5

71

cT3b cN0

8

2,5

-

n.a.

2,5

pos. (P, Ln)

AHT

6

77

cT3b cN0

7

10,4

-

n.a.

10,4

pos. (P)

AHT

7

74

cT3b cN0

7

27,5

-

n.a.

0,2

pos. (P)

AHT

8

60

cT2 cN0

7

13

-

3

13

pos. (Ln)

TUR-P, Seed

9

65

cT2 cN0

9

26,9

n.a.

n.a.

-

pos. (lLn)

RT P

10

63

pT1c cN0

6

4,71

3,49

n.a.

2,2

pos. (P)

RP, AHT

11

67

pT2a cN0

7

4,78

0,69

3

1,92

pos. (Ln)

RP

12

58

pT2b pN0

7

8,24

< 0,04

1

0,51

pos. (Ln)

RP, LAD

13

68

pT2c pN0

9

12,1

0,23

7

0,48

pos. (P, Ln)

RP, LAD

14

66

pT2c cN0

5

3,35

0,1

10

2,21

pos. (Ln)

RP, LAD

15

65

pT2c cNx

7

7,45

0,13

<3

1,19

pos. (P, Ln)

RP, AHT

16

71

pT3a cN0

10

n.a.

n.a.

n.a.

6,5

pos. (P, Ln)

TUR-P, AHT

17

71

pT3a pN1

7

n.a.

n.a.

n.a.

4,8

pos. (Ln)

RP, LAD, AHT

18

71

pT3a pN0

5

7,76

0,03

6

1,25

pos. (P, Ln)

RP, LAD, RT P

19

69

pT3a cN0

7

15,4

0,18

6

0,65

neg.

RP

20

71

pT3a pN0

6

n.a.

0,38

> 12

0,75

neg.

RP, LAD

21

65

pT3b pN1

7

14

0,89

4

1,69

pos. (Ln)

RP, LAD, AHT

22

70

pT3b pN0

7

43

0,62

3

1,89

pos. (P, Ln)

RP, LAD, AHT

23

69

pT3b pN0

7

14,3

0,17

2,5

0,42

pos. (Ln)

RP, LAD

24

55

pT3b pN0

6

15

0,35

n..a.

1,2

pos. (Ln)

RP, LAD

25

68

pT4 pN0

7

n.a.

n.a.

6,3

3

pos. (P, bone)

RP, LAD, AHT

26

74

pT3a pN0

5

7,76

0,03

< 3

2,87

pos. (Ln)

RP, LAD, RT P+Ln

  1. Abbreviation: stage: initial tumor stage; iPSA: initial PSA value (ng/ml); PSA nadir: minimal PSA value after prostatectomy (ng/ml); dt PSA: PSA doubling in months; PET/CT: FEC-PET/CT result (P: FEC uptake in prostate gland or prostate bed; Ln: FEC uptake in lymph nodes; Bo: FEC uptake in bone; Bl: FEC uptake in bladder).
  2. Previous therapy: Therapeutic modalities before PET/CT-planned irradiation. RT: radiotherapy (P: prostate; Ln: pelvic lymph nodes); AHT: anti-hormonal therapy; RP: radical prostatectomy; LAD: pelvic lymphadenectomy. n.a.: not available.